Literature DB >> 17550991

Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study.

S Zoccolella1, E Beghi, G Palagano, A Fraddosio, V Guerra, V Samarelli, V Lepore, I L Simone, P Lamberti, L Serlenga, G Logroscino.   

Abstract

OBJECTIVE: To measure survivorship and predictors of prognosis of amyotrophic lateral sclerosis (ALS).
METHODS: Incident cases, diagnosed in the 1998-1999 period and classified according to the El Escorial criteria, were enrolled from a prospective population based registry established in Puglia, Southern Italy, with a reference population of 4,025,329. Cases were followed up until death or 30 June 2004.
RESULTS: We identified 130 incident cases of ALS while four were lost to follow-up. Median survival was 28 months from first symptoms and 16 months from diagnosis, while cumulative survivorship at 4 years was approximately 30%. Advanced age (>75 years: hazard ratio (HR) 7.5; 95% CI 1.9 to 29.6; p = 0.004) and bulbar or generalised (HR 1.8; 95% CI 1.1 to 3.0; p = 0.01) onset of symptoms were independent predictors of adverse survival. After stratifying patients according to site of first symptoms, age was a predictor of death among spinal (HR for patients aged >75 years compared with patients aged 45 years or less: HR 11; 95% CI 1.5 to 78.5; p = 0.01) but not among bulbar ALS (HR 4.5; 95% CI 0.4 to 46.5; p = 0.2). Among spinal onset cases, cases with predominant upper motoneuronal (UMN) involvement presented with a borderline significant better survivorship (HR 0.5; 95% CI 0.2 to 1.3; p = 0.1)
CONCLUSIONS: Bulbar signs and advanced age among subjects with spinal onset were indicators of poor prognosis while El Escorial category at entry did not predict survival. Among subjects with spinal onset of the disease, a trend for a better survivorship of subjects with UMN signs was noted.

Entities:  

Mesh:

Year:  2007        PMID: 17550991     DOI: 10.1136/jnnp.2007.118018

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  35 in total

1.  Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression.

Authors:  Robert Küffner; Neta Zach; Raquel Norel; Johann Hawe; David Schoenfeld; Liuxia Wang; Guang Li; Lilly Fang; Lester Mackey; Orla Hardiman; Merit Cudkowicz; Alexander Sherman; Gokhan Ertaylan; Moritz Grosse-Wentrup; Torsten Hothorn; Jules van Ligtenberg; Jakob H Macke; Timm Meyer; Bernhard Schölkopf; Linh Tran; Rubio Vaughan; Gustavo Stolovitzky; Melanie L Leitner
Journal:  Nat Biotechnol       Date:  2014-11-02       Impact factor: 54.908

Review 2.  Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin.

Authors:  Benoît Marin; Giancarlo Logroscino; Farid Boumédiene; Anaïs Labrunie; Philippe Couratier; Marie-Claude Babron; Anne Louise Leutenegger; Pierre Marie Preux; Ettore Beghi
Journal:  Eur J Epidemiol       Date:  2015-10-12       Impact factor: 8.082

Review 3.  The phenotypic variability of amyotrophic lateral sclerosis.

Authors:  Bart Swinnen; Wim Robberecht
Journal:  Nat Rev Neurol       Date:  2014-10-14       Impact factor: 42.937

4.  Stratification of ALS patients' survival: a population-based study.

Authors:  Benoît Marin; Philippe Couratier; Simona Arcuti; Massimiliano Copetti; Andrea Fontana; Marie Nicol; Marie Raymondeau; Giancarlo Logroscino; Pierre Marie Preux
Journal:  J Neurol       Date:  2015-10-30       Impact factor: 4.849

5.  MR spectroscopy findings in early stages of motor neuron disease.

Authors:  M M van der Graaff; C Lavini; E M Akkerman; Ch B Majoie; A J Nederveen; A H Zwinderman; F Brugman; L H van den Berg; J M B V de Jong; M de Visser
Journal:  AJNR Am J Neuroradiol       Date:  2010-08-26       Impact factor: 3.825

Review 6.  Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?

Authors:  Neta Zach; David L Ennist; Albert A Taylor; Hagit Alon; Alexander Sherman; Robert Kueffner; Jason Walker; Ervin Sinani; Igor Katsovskiy; Merit Cudkowicz; Melanie L Leitner
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

7.  Association of ALS with head injury, cigarette smoking and APOE genotypes.

Authors:  Silke Schmidt; Lydia Coulter Kwee; Kelli D Allen; Eugene Z Oddone
Journal:  J Neurol Sci       Date:  2010-02-02       Impact factor: 3.181

8.  Differentiation of CD133+ stem cells from amyotrophic lateral sclerosis patients into preneuron cells.

Authors:  Maria Teresa González-Garza; Héctor R Martínez; Enrique Caro-Osorio; Delia E Cruz-Vega; Martin Hernández-Torre; Jorge E Moreno-Cuevas
Journal:  Stem Cells Transl Med       Date:  2013-01-22       Impact factor: 6.940

9.  Statins accelerate disease progression and shorten survival in SOD1(G93A) mice.

Authors:  Xiaowei W Su; Wint Nandar; Elizabeth B Neely; Zachary Simmons; James R Connor
Journal:  Muscle Nerve       Date:  2016-05-19       Impact factor: 3.217

Review 10.  Amyotrophic lateral sclerosis.

Authors:  Lokesh C Wijesekera; P Nigel Leigh
Journal:  Orphanet J Rare Dis       Date:  2009-02-03       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.